To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
LONDON (AFP-Jiji) — Doctors in Britain have hailed a pioneering treatment for an aggressive form of leukemia, after a teenager became the first patient to be given a new therapy and went into remission.
The 13-year-old girl, identified only as Alyssa, was diagnosed with T-cell acute lymphoblastic leukemia in 2021.
But her blood cancer did not respond to conventional treatment, including chemotherapy and a bone marrow transplant.
She was enrolled on a clinical trial of a new treatment at London’s Great Ormond Street Hospital for Children (GOSH) using genetically engineered immune cells from a healthy volunteer.
In 28 days her cancer was in remission, allowing her to receive a second bone marrow transplant to restore her immune system.
Six months on, she is “doing well” back home in Leicester, central England, and receiving follow-up care.
“Without this experimental treatment, Alyssa’s only option was palliative care,” the hospital said in a statement on Dec. 11.
Robert Chiesa, a GOSH consultant, said her turnaround had been “quite remarkable,” although the results still needed to be monitored and confirmed in the next few months.
Acute lymphoblastic leukemia is the most common kind of cancer in children and affects cells in the immune system, known as B-cells and T-cells, which fight and protect against viruses.
GOSH said Alyssa was the first patient known to have been given base-edited T-cells, which involves chemically converting single nucleotide bases — letters of the DNA code — which carry instructions for a specific protein.
Researchers at GOSH and University College London helped develop the use of genome-edited T-cells to treat B-cell leukemia in 2015.
But to treat some other types of leukemia the team had to overcome the challenge that T-cells designed to recognize and attack cancerous cells had ended up killing each other during the manufacturing process.
Multiple additional DNA changes were needed to the base-edited cells to allow them to target cancerous cells without damaging each other.
